Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma

[thumbnail of Original Article]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
4MB
[thumbnail of Supplementary Information] Other (Supplementary Information)
959kB

Item Type:Article
Title:Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma
Creators Name:Cichocki, F., Bjordahl, R., Goodridge, J.P., Mahmood, S., Gaidarova, S., Abujarour, R., Davis, Z.B., Merino, A., Tuininga, K., Wang, H., Kumar, A., Groff, B., Witty, A., Bonello, G., Huffman, J., Dailey, T., Lee, T.T., Malmberg, K.J., Walcheck, B., Höpken, U., Rehm, A., Valamehr, B. and Miller, J.S.
Abstract:Allogeneic natural killer (NK) cell adoptive transfer is a promising treatment for several cancers but is less effective for the treatment of multiple myeloma. In this study, we report on quadruple gene-engineered induced pluripotent stem cell (iPSC)-derived NK cells designed for mass production from a renewable source and for dual targeting against multiple myeloma through the introduction of an NK cell-optimized chimeric antigen receptor (CAR) specific for B cell maturation antigen (BCMA) and a high affinity, non-cleavable CD16 to augment antibody-dependent cellular cytotoxicity when combined with therapeutic anti-CD38 antibodies. Additionally, these cells express a membrane-bound interleukin-15 fusion molecule to enhance function and persistence along with knock out of CD38 to prevent antibody-mediated fratricide and enhance NK cell metabolic fitness. In various preclinical models, including xenogeneic adoptive transfer models, quadruple gene-engineered NK cells consistently demonstrate durable antitumor activity independent of exogenous cytokine support. Results presented here support clinical translation of this off-the-shelf strategy for effective treatment of multiple myeloma.
Keywords:B-Cell Maturation Antigen, Multiple Myeloma, NK Cell Lectin-Like Receptor Subfamily D, Natural Killer Cell Receptors, Natural Killer Cells
Source:Nature Communications
ISSN:2041-1723
Publisher:Nature Publishing Group
Volume:13
Number:1
Page Range:7341
Date:29 November 2022
Official Publication:https://doi.org/10.1038/s41467-022-35127-2
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library